Overview of randomized and evaluable patients. By November 30, 2008, 1242 patients were randomized. Eleven of 312 patients randomized to imatinib 400 mg, 11 of 304 randomized to imatinib 800 mg, 20 of 338 randomized to imatinib in combination with IFN, 22 of 158 randomized to imatinib in combination with araC, and 20 of 131 randomized to imatinib after IFN failure underwent transplantation. The 84 patients who underwent transplantation were analyzed in 3 groups according to the reason of allo SCT: group I (early transplantation in low-risk patients, EBMT score 0-1), group II (imatinib failure in first CP), and group III (advanced disease).